US2009000861 COMPOUNDS WITH MDR1-INVERSE ACTIVITY

1. (WO2009102433) COMPOUNDS WITH MDR1-INVERSE ACTIVITY

Latest bibliographic data on file with the International Bureau

Pub. No.:		WO/2009/102433		International Application No.:		PCT/US2009/000861
Publication Date:		20.08.2009		International Filing Date:		10.02.2009

IPC:

A61K 31/404 (2006.01), A61K 31/44 (2006.01), A61P 43/00 (2006.01)

Applicants:

THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer 6011 Executive Blvd., Suite 325 Rockville, MD 20852-3804 (US) (For All Designated States Except US).
INSTITUTE OF ENZYMOLOGY, BIOLOGICAL RESEARCH CENTER, HUNGARIAN ACADEMY OF SCIENCES [HU/HU]; Karolina út 29, H-1113 Budapest (HU) (For All Designated States Except US).
HALL, Matthew, D. [AU/US]; (US) (For US Only).
GOTTESMAN, Michael, M. [US/US]; (US) (For US Only).
HELLAWELL, Jennifer, L. [US/US]; (US) (For US Only).
LUDWIG, Joseph, A. [US/US]; (US) (For US Only).
FALES, Henry, M. [US/US]; (US) (For US Only).
SALAM, Noeris, K. [AU/US]; (US) (For US Only).
SZAKÁCS, Gergely [HU/HU]; (HU) (For US Only)

Inventors:

HALL, Matthew, D.; (US).
GOTTESMAN, Michael, M.; (US).
HELLAWELL, Jennifer, L.; (US).
LUDWIG, Joseph, A.; (US).
FALES, Henry, M.; (US).
SALAM, Noeris, K.; (US).
SZAKÁCS, Gergely; (HU)

Agent:

RUPERT, Wayne, W.; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US)

Priority Data:

61/027,712

11.02.2008

Title

(EN) COMPOUNDS WITH MDR1-INVERSE ACTIVITY
(FR) COMPOSÉS À ACTIVITÉ MDR1 INVERSE

Abstract:

(EN)Disclosed herein are drug compounds that have MDR-inverse activity and thus are effective against multidrug-resistant cells. Exemplary compounds disclosed herein have the following structure: (I). Examples of the disclosed compounds have been found to have, inter alia, efficacy in directly treating multidrug resistant cells, rendering multidrug resistant cells susceptible to other chemotherapeutics and in some instances reversing multidrug resistance.
(FR)La présente invention concerne des composés médicamenteux qui ont une activité MDR inverse et qui sont donc efficaces contre les cellules multirésistantes. Des exemples de composés décrits ici ont la structure suivante : (I). Des exemples des composés décrits se sont avérés avoir, entre autre, une efficacité dans le traitement direct de cellules multirésistantes, rendant les cellules multirésistantes sensibles à d’autres produits chimiothérapeutiques et dans certains cas dans l’inversion de la multirésistance.

Designated States:

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Org. (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (EAPO) (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (OAPI) (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Publication Language:	English (EN)
Filing Language:	English (EN)